Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.39B |
$13.13
+10.15%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.37B |
$25.14
-1.99%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.36B |
$40.56
-0.86%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$1.34B |
$12.48
+5.18%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.31B |
$4.39
+6.16%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.30B |
$8.00
+2.76%
|
|
ANAB
AnaptysBio, Inc.
Company develops immunology therapeutics targeting autoimmune/inflammatory diseases (e.g., rosnilimab, ANB033, ANB101).
|
$1.28B |
$45.65
-1.43%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.28B |
$10.47
-2.65%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.28B |
$14.31
+5.88%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.27B |
$7.34
-3.74%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.25B |
$18.39
+1.27%
|
|
QURE
uniQure N.V.
Core business is development and commercialization of gene therapies (e.g., AMT-130) using viral vectors, i.e., direct gene therapy products.
|
$1.25B |
$22.85
+3.96%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.24B |
$4.55
-7.14%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.24B |
$16.79
-3.89%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.23B |
$4.12
-1.56%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.23B |
$19.43
-1.67%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.21B |
$7.53
+1.62%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.21B |
$26.08
+0.31%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.19B |
$9.84
-0.81%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.18B |
$12.12
+5.16%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.16B |
$26.05
-4.84%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$1.16B |
$39.98
-1.88%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$1.15B |
$15.02
+2072.72%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.11B |
$24.39
+1.46%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.10B |
$99.88
-3.94%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$1.09B |
$4.58
-1.82%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$1.08B |
$16.76
+2.51%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$1.05B |
$17.00
+0.24%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.05B |
$4.66
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.05B |
$72.46
+0.92%
|
Showing page 8 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
